Brain

International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific Assembly

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF), in partnership with the National Medical Association...

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,...

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,...

New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer’s Disease

STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...

Orphan Drugs and Rare Diseases Conference (Boston, MA, United States – October 17-18, 2024) – Navigating Orphan Drugs & Rare Diseases from Regulation to Detection & Precision Treatments – ResearchAndMarkets.com

MIRA Pharmaceuticals Unveils Ketamir-2’s Principal Metabolite: Nor-Ketamir – a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments.MIAMI, FL / ACCESSWIRE / August...

FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team

error: Content is protected !!